Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections Clinical Trial

Official title:

An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05092386
• Other study ID #: PRO-PCV-1001
• Status: Recruiting
• Phase: Phase 1
• Start date: January 3, 2023
• Est. completion date: June 6, 2024

Study information

• Verified date: May 2024
• Source: Sinovac Biotech Co., Ltd
• Contact: Yanxia Wang, Master
• Phone: 13613816598
• Email: wangyanxia99[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial of the a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to preliminary evaluate the safety and immunogenicity of the study vaccine

Description:

This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial in subjects aged 2 months (minimum 6 weeks) and above. The experimental vaccine was manufactured by Sinovac Research & Development Co., Ltd. .And one of the positive control vaccine was manufactured by WALVAX Biotechnology Co., Ltd( WALVAX PCV13) ,the other manufactured by Pfizer(Pfizer PCV13).A total of 310 subjects including 20 adults aged 18-49 years,20 adolescents and children aged 6~7 years ,60 children aged 2-5 years,60 infants aged 12~23 months,60 infants aged 7 ~11 months,60 infants aged 2 months (minimum 6 weeks), and 30 infants aged 3 months will be enrolled.Subjects will be assigned to receive one dose , two doses ,three doses or four doses of experimental vaccine or different positive control vaccines . Subjects aged 18-49 years will receive one dose of experimental vaccine.Subjects aged 6~17 years will receive one dose of experimental vaccine.Subjects aged 2~5 years will be randomly divided into two groups in a ratio of 1:1,and each group will receive one dose of experimental vaccine or control vaccine(WALVAX PCV13）.Subjects aged 7 ~ 11 months and subjects aged 12 ~23 months will be randomly divided into two groups in a 1:1 ratio,the subjects aged 12 ~ 23 months will receive two doses of experimental vaccine or control vaccine on the schedule of month 0,2 .Subjects aged 7 ~11 months will receive 3 doses of experimental vaccine or control vaccine (WALVAX PCV13）on the immunization schedule of month 0,2,4.Subjects aged 3 months will receive 4 doses of experimental vaccine.Subjects aged 2 months will be randomly divided into 2 groups in a 1:1 ratio and each group will receive 4 doses of experimental vaccine or control vaccine (Pfizer PCV13).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 310
• Est. completion date: June 6, 2024
• Est. primary completion date: June 6, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Weeks to 49 Years

Eligibility

Inclusion Criteria:

• Healthy infants aged 2 months (minimum 6 weeks), healthy infants aged 3 months, healthy infants aged 7 ~ 11 months, healthy infants aged 12~ 23 months, healthy children aged 2~ 5 years, healthy adolescent and children aged 6~ 17 years, healthy adults aged 18~ 49 years;

• Proven legal identification and vaccination certificate (vaccination certificate is required for those aged 5 and below);

• The subject and/or guardian can understand and voluntarily sign the informed consent form.

Exclusion Criteria:

• Have received pneumococcal polysaccharide vaccine or pneumococcal polysaccharide conjugate vaccine;

• Have Bacterial pneumonia or invasive pneumococcal infectious disease (IPD) caused by pneumococcus confirmed by sputum culture;

• History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;

• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;

• Autoimmune disease or immunodeficiency / immunosuppression;

• Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;

• Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;

• History of thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy due to any circumstance;

• Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;

• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;

• History of alcohol or drug abuse;

• Receipt of blood products within in the past 3 months;

• Receipt of other investigational drugs in the past 30 days;

• Receipt of attenuated live vaccines in the past 14 days;

• Receipt of inactivated or subunit vaccines in the past 7 days;

• Acute diseases or acute exacerbation of chronic diseases in the past 7 days;

• Axillary temperature >37.0°C;

• According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Related Conditions & MeSH terms

• Pneumococcal Infections

Intervention

Biological:
• Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
The investigational vaccine was manufactured by Sinovac Research & Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
• Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)
The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
• Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)
The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.

Locations

Country	Name	City	State
China	Henan Center for Diseases Control and Prevention	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Life Sciences Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety index-incidence of adverse reactions	Incidence of adverse reactions 0 to 30 days after each dose of experimental vaccine	Day 0-30 after each dose of experimental vaccine
Secondary	Safety index-incidence of adverse reactions	Incidence of adverse reactions 0 to 7 days after each dose of experimental vaccine	Day 0-7 after each dose of experimental vaccine
Secondary	Safety index-incidence of abnormal indicators	Incidence of abnormal indicators of Blood routine, blood biochemistry and urine routine 3 days after vaccination in subjects aged 2 years and older	Day 3 after vaccination after each dose of experimental vaccine
Secondary	Safety index-Incidence of serious adverse events during the safety observation period	Incidence of serious adverse events during the safety observation period, including 1 month after vaccination in subject aged 6 years and older, and 6 months after primary immunization and 1 month after booster immunization in subject aged 2 months (minimum 6 weeks) to 5 years(if any)	1 month after vaccination ,6 months after primary immunization or 1 month after booster immunization
Secondary	Immunogenicity index-Geometric mean concentrations (GMC) and GMI of specific IgG for each serotype	Geometric mean concentrations (GMC) and GMI of specific IgG for each serotype at 30 days after vaccination in subjects of all age groups	Day 30 after vaccination
Secondary	Immunogenicity index-Geometric mean titers (GMT) and GMI of serotype specific opsonophagocytic antibody OPA for each serotype	Geometric mean titers (GMT) and GMI of serotype specific opsonophagocytic antibody OPA for each serotype at 30 days after vaccination in subjects of all age groups	Day 30 after vaccination
Secondary	Immunogenicity index-Seropositive rates,GMCs and GMI of serum specific antibody	Seropositive rates of IgG concentration =0.35µg/mL, =1.0µg/mL, geometric mean concentration (GMCs) and GMI of serum specific antibody at 30 days after primary immunization in subjects of all age groups	Day 30 after vaccination
Secondary	Immunogenicity index-Proportion of OPA =1:8 of each serum and geometric mean titer (GMT)	Proportion of OPA =1:8 of each serum and geometric mean titer (GMT)in subjects of all age groups at 30 days after primary immunization	Day 30 after vaccination
Secondary	Immunogenicity index-Seropositive rates of IgG concentration =0.35µg/mL, =1.0µg/mL, geometric mean concentration (GMC)	Seropositive rates of IgG concentration =0.35µg/mL, =1.0µg/mL, geometric mean concentration (GMC) in subjects aged 2 months (Minimum 6 weeks), 3 months and 7 ~ 11 months at 30 days before and after booster immunization	Day 30 before and after booster immunization
Secondary	Immunogenicity index-Proportion of OPA =1:8 for each serotype and geometric mean titer (GMT)	Proportion of OPA =1:8 for each serotype and geometric mean titer (GMT) in subjects aged 2 months (Minimum 6 weeks), 3 months, and 7~ 11 months at 30 days before and after booster immunization	Day 30 before and after booster immunization